X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2024/01/17/2810651/0/en/Windtree-Therapeutics-Announces-License-Agreement-with-Lee-s-Pharmaceuticals-to-Develop-and-Commercialize-Istaroxime-Dual-Mechanism-SERCA2a-Activators-and-Rostafuroxin-for-Greater-.html
https://www.globenewswire.com//news-release/2024/01/02/2802918/0/en/Windtree-Therapeutics-Announces-Reduction-In-Arrythmias-In-A-New-Study-With-Istaroxime-And-A-Pure-SERCA2a-Activator.html
https://www.globenewswire.com//news-release/2023/12/18/2797777/0/en/Windtree-Therapeutics-Announces-the-Start-of-Patient-Dosing-In-Phase-2-SEISMiC-Extension-Study-of-Istaroxime-in-Early-Cardiogenic-Shock.html
https://www.globenewswire.com/news-release/2023/06/05/2681890/0/en/Windtree-Therapeutics-to-Host-Virtual-R-D-and-Investor-Day-Focusing-on-the-Cardiogenic-Shock-Market-Istaroxime-Company-Strategy-and-Planned-Near-Term-Milestones.html
https://www.globenewswire.com/news-release/2023/04/27/2656271/0/en/Windtree-Therapeutics-Announces-Publication-from-Its-SEISMiC-Pre-Cardiogenic-Shock-Study-Comparing-Two-Doses-of-Istaroxime.html
https://www.globenewswire.com/news-release/2023/03/06/2621027/0/en/Windtree-Finds-Cardiogenic-Shock-Has-High-Cost-of-US-Patient-Care-and-Plans-Innovation-with-the-Unique-Profile-of-Istaroxime.html
https://www.globenewswire.com/news-release/2023/02/24/2615205/0/en/Windtree-Therapeutics-Announces-Issuance-of-New-Istaroxime-Patent-from-U-S-Patent-and-Trademark-Office.html
https://www.globenewswire.com/news-release/2022/10/25/2540773/0/en/Windtree-Announces-Notice-of-Allowance-from-the-US-Patent-and-Trademark-Office-for-a-New-Istaroxime-Patent.html
https://www.globenewswire.com/news-release/2022/09/26/2522465/0/en/Windtree-Therapeutics-Announces-Istaroxime-Late-Breaker-Abstract-from-its-Positive-Phase-2-Study-in-Early-Cardiogenic-Shock-SEISMiC-to-be-Presented-at-Heart-Failure-Society-of-Amer.html
https://www.fiercebiotech.com/biotech/after-data-win-windtree-refuses-be-disheartened-bear-market-considers-strategic-options
https://www.globenewswire.com/news-release/2022/06/29/2471199/0/en/Windtree-Is-Leveraging-Positive-Istaroxime-Early-Cardiogenic-Shock-Results-to-Proactively-Engage-in-Licensing-Discussions-and-Explore-Strategic-Opportunities-to-Realize-Greater-Sha.html
https://www.globenewswire.com/news-release/2022/05/23/2448410/0/en/Journey-Medical-Corporation-to-Present-at-the-B-Riley-Securities-22nd-Annual-Institutional-Investor-Conference.html
https://www.marketwatch.com/story/windtree-therapeutics-sees-positive-results-for-istaroxime-271650453432
https://www.globenewswire.com/news-release/2021/10/25/2319746/0/en/Windtree-Announces-Notice-of-Allowance-from-the-US-Patent-and-Trademark-Office-for-a-New-Istaroxime-Patent.html
https://www.globenewswire.com/news-release/2021/10/14/2314390/19989/en/Clarus-Therapeutics-to-Present-New-Real-World-Experience-Data-for-JATENZO-testosterone-undecanoate-at-the-22nd-Annual-Fall-Scientific-Meeting-of-SMSNA.html
https://www.globenewswire.com/news-release/2021/10/14/2314160/0/en/Windtree-Hosting-Key-Opinion-Leader-Webinar-on-Istaroxime-for-the-Treatment-of-Acute-Heart-Failure-and-the-Upcoming-Data-in-Early-Cardiogenic-Shock.html
Market Place
Share 
